-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SOCuvxf7ZsnnTk2zWxJSW+R/akfIuwKnYxF0p/YQYms9615aHCN4xoHqP/cTZXNW XdAQcjXgESjuIJLOvJB0/A== 0000950144-99-005191.txt : 19990503 0000950144-99-005191.hdr.sgml : 19990503 ACCESSION NUMBER: 0000950144-99-005191 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19990610 FILED AS OF DATE: 19990430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESPONSE ONCOLOGY INC CENTRAL INDEX KEY: 0000763098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 621212264 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: SEC FILE NUMBER: 001-09922 FILM NUMBER: 99607987 BUSINESS ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 BUSINESS PHONE: 9017617000 MAIL ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 FORMER COMPANY: FORMER CONFORMED NAME: RESPONSE TECHNOLOGIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19891221 DEF 14A 1 RESPONSE ONCOLOGY, INC 1 SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant to ss 240.14a-11(c) or ss 240.14a-12
Response Oncology, Inc. - -------------------------------------------------------------------------------- (Name of Registrant as Specified In Its Charter) - -------------------------------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: [ ] Fee paid previously with preliminary materials: [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 2 RESPONSE ONCOLOGY, INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 10, 1999 NOTICE IS HEREBY GIVEN that the 1999 Annual Meeting of the Shareholders of Response Oncology, Inc. (the "Annual Meeting") will be held at the offices of Response Oncology, Inc. (the "Company"), 1805 Moriah Woods Blvd., Memphis, Tennessee 38117 on Thursday, June 10, 1999, at 11:00 a.m., local time, for the following purposes: 1. To elect three Class III directors to serve one year terms ending in 2000, or until their successors have been duly elected and qualified. 2. To ratify the selection of KPMG LLP as the Company's independent auditors for 1999. Only shareholders of the Company of record as of the close of business on April 20, 1999 will be entitled to notice of, and to vote at, the Annual Meeting and any adjournment thereof. There is enclosed, as a part of this Notice, a Proxy Statement which contains further information regarding the meeting and the above proposals. BY ORDER OF THE BOARD OF DIRECTORS Mary E. Clements Secretary April 25, 1999 - ------------------------------------------------------------------------------ SHAREHOLDERS WHO DO NOT EXPECT TO ATTEND THE MEETING ARE REQUESTED TO COMPLETE, DATE, SIGN AND RETURN THE ACCOMPANYING PROXY IN THE ENCLOSED ENVELOPE. SHAREHOLDERS WHO ATTEND THE MEETING MAY VOTE IN PERSON EVEN IF THEY HAVE ALREADY SENT IN A PROXY. - ------------------------------------------------------------------------------ 3 RESPONSE ONCOLOGY, INC. 1805 MORIAH WOODS BLVD. MEMPHIS, TENNESSEE 38117 ---------- PROXY STATEMENT ---------- GENERAL INFORMATION THIS PROXY STATEMENT is provided in connection with the solicitation of proxies by the Board of Directors of Response Oncology, Inc. (the "Company") for use at the annual meeting of shareholders to be held on June 10, 1999, (the "Annual Meeting") and any adjournment thereof. The mailing address of the principal executive offices of the Company is 1805 Moriah Woods Blvd., Memphis, Tennessee 38117. This Proxy Statement and the Proxy Form, Notice of Meeting and the Company's Annual Report, all enclosed herewith, are first being mailed to the shareholders of the Company on or about May 10, 1999. No person is authorized to give any information or to make any representation not contained in this Proxy Statement and, if given or made, such information or representation should not be relied upon as having been authorized. This Proxy Statement does not constitute the solicitation of a proxy in any jurisdiction where, or from any person to whom it is unlawful to make such proxy solicitation. The delivery of this Proxy Statement shall not, under any circumstances, imply that there has not been any change in the information set forth herein since the date of the Proxy Statement. THE PROXY The solicitation of proxies is being made on behalf of the Board of Directors of the Company primarily by the use of the mails. The cost of preparing and mailing this Proxy Statement and accompanying material, and the cost of any supplementary solicitation, which may be made by mail, telephone, telegraph or personally by officers and employees of the Company (who will receive no additional compensation for such activities), will be borne by the Company. The shareholder giving the proxy has the power to revoke it by delivering written notice of such revocation to the Secretary of the Company prior to the Annual Meeting or by attending the meeting and voting in person. Arrangements will also be made with brokerage houses and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial owners of shares held of record by such persons. Shares of the Company's common stock, $.01 par value per share ("Common Stock") represented by properly executed proxies, unless previously revoked, will be voted in accordance with the instructions on such proxies. If no instruction is indicated on the proxy, the named holders of the proxies will vote such shares of Common Stock (i) FOR the election of all Class III director nominees named in the Proxy Statement; and (ii) FOR the ratification and selection of KPMG LLP as the Company's independent auditors for 1999. The named holders of proxies also will use their discretion in voting the Shares of Common Stock in connection with any other business that properly may come before the Annual Meeting. VOTING RIGHTS Each outstanding share of Common Stock is entitled to one vote. Cumulative voting is not permitted. Only shareholders of record at the close of business on April 20, 1999 will be entitled to notice of, and to vote at, the Annual Meeting and any adjournment thereof. As of the close of business on April 20, 1999, the Company had outstanding 2 4 11,931,731 shares of Common Stock. Of the total number of outstanding shares of Common Stock on April 20, 1999, the directors and executive officers of the Company, consisting of 11 persons, owned 909,552 shares comprising 7.62% of such total. No specific provision of the Tennessee Business Corporation Act, the Company's charter or the Company's Bylaws addresses the issue of abstentions or broker non-votes. Brokers holding shares for beneficial owners must vote those shares according to the specific instructions they receive from the owners. However, brokers or nominees holding shares for beneficial owners may not have discretionary voting power and may not have received voting instructions from the beneficial owner with respect to voting on certain proposals. In such cases, absent specific voting instructions from the beneficial owner, the broker may not vote on these proposals. This results in what is known as a "broker non-vote". A "broker non-vote" will not be counted as votes cast but will be counted for the purposes of determining the existence of the quorum. Because the election of directors and ratification of the selection of independent auditors or routine matters for which specific instructions from beneficial owners will not be required, the Company does not anticipate that any "broker non-votes" will arise in the context of the election of directors or the ratification of the selection of independent auditors. Votes "withheld" from a director-nominee or from the ratification of the selection of independent auditors have the effect of a negative vote because a plurality of the votes cast at the Annual Meeting is required for the election of each director and the ratification of the selection of independent auditors. 3 5 REQUIRED VOTE Approval of each matter submitted to the shareholders of the Company for a vote at the Annual Meeting will require the affirmative vote of a majority of the shares of Common Stock voting at the Annual Meeting in person or by proxy. OWNERSHIP OF THE COMPANY'S COMMON STOCK SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS. The following table sets forth information as of April 20, 1999, regarding each person known to the Company to be the beneficial owner of more than five percent of its Common Stock:
AMOUNT AND NATURE OF NAME OF BENEFICIAL OWNER BENEFICIAL OWNER PERCENT OF CLASS (1) ------------------------ ---------------- -------------------- Dalton, Greiner, Hartman, Maher & Co. 1100 Fifth Avenue South, Ste. 301 Naples, Florida 34102 868,800 7.28% Dimensional Fund Advisors, Inc. 1299 Ocean Avenue, 11th Floor Santa Monica, CA 90401 803,949 6.73% William D. Grant One Ward Parkway, Ste. 130 Kansas City, MO 64112 995,577 8.34% Southern Fiduciary Trust 2325 Crestmoor Road, Ste. 202 Nashville, TN 37215 626,629 5.25% William H. West, M.D. 1805 Moriah Woods Blvd. Memphis, TN 38117 900,129 (2) 7.38%
(1) The percentages shown are based on 11,931,731 shares of Common Stock outstanding on April 20, 1999 plus, as to each individual and group listed, the number of shares of Common Stock deemed to be owned by such holder, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, assuming conversion of the Company's Series A Preferred Stock and exercise of all options and warrants held by such holder, which stock, options and warrants may be converted or exercised within sixty (60) days of April 20, 1999. (2) Includes 259,149 shares of Common Stock which Dr. West has the right to acquire pursuant to the exercise of options. 4 6 SECURITY OWNERSHIP OF MANAGEMENT The following table sets forth the beneficial ownership of Common Stock all as of April 20, 1999 by (i) each director, (ii) each director nominee, (iii) each executive officer named in the Summary Compensation Table, and (iv) all directors, nominees and executive officers as a group. None of the Company's executive officers or directors is a beneficial owner of any of the Company's Series A Preferred Stock.
AMOUNT AND NATURE OF PERCENT OF NAME OF BENEFICIAL OWNER BENEFICIAL OWNERSHIP CLASS (1) ------------------------ -------------------- ---------- Frank M. Bumstead Director 126,781(2) 1.06% Joseph T. Clark Director, President and Chief Executive Officer 388,349(3) 3.15% Mary E. Clements Chief Financial Officer 130,000(4) 1.08% W. Thomas Grant II Director 121,378(5) 1.02% P. Anthony Jacobs Director 46,076(6) * Leonard A. Kalman, M.D. Director 43,020(7) * Lawrence N. Kugelman Director 19,000(8) * Kenneth L. Scott Chief Operating Officer 157,731(9) 1.30% Carlton N. Sedberry EVP Development 126,555(10) 1.05% James R. Seward Director 39,117(10) * William H. West, M.D. Chairman 900,129(12) 7.38% ALL DIRECTORS AND OFFICERS AS A GROUP (11 PERSONS) 2,098,136(13) 15.99%
(1) The percentages shown are based on 11,931,731 shares of Common Stock outstanding on April 20, 1999 plus, as to each individual and group listed, the number of shares of Common Stock deemed to be owned by such holder, for purposes of Rule 5 7 13d-3 under the Securities Exchange Act of 1934, assuming conversion of the Company's Series A Preferred Stock and exercise of all options held by such holder, which stock options may be converted or exercised within sixty (60) days of April 20, 1999. (2) Includes 18,000 shares of Common Stock which Mr. Bumstead has a right to acquire pursuant to the exercise of options and warrants. (3) Includes 383,549 shares of Common Stock which Mr. Clark has the right to acquire pursuant to the exercise of options. (4) Represents shares of Common Stock which Ms. Clements has the right to acquire pursuant to the exercise of options. (5) Includes 18,000 shares of Common Stock which Mr. Grant has the right to acquire pursuant to the exercise of options. (6) Includes 18,000 shares of Common Stock which Mr. Jacobs has the right to acquire pursuant to the exercise of options. (7) Includes 43,000 shares of Common Stock which Dr. Kalman has the right to acquire pursuant to the exercise of options and 20 shares held by his wife in an IRA. (8) Includes 17,000 shares of Common Stock which Mr. Kugelman has the right to acquire pursuant to the exercise of options. (9) Includes 157,331 shares of Common Stock which Mr. Scott has the right to acquire pursuant to the exercise of options. (10) Represents shares of common stock which Mr. Sedberry has the right to acquire pursuant to the exercise of options. (11) Includes 18,000 shares of Common Stock which Mr. Seward has the right to acquire pursuant to the exercise of options. (12) Includes 259,149 shares of Common Stock which Dr. West has the right to acquire pursuant to the exercise of options. (13) Includes 1,188,584 shares of Common Stock as to which various officers and directors have rights to acquire pursuant to the exercise of options and conversion rights on note payments. * Represents less than 1% of total outstanding Common Stock 6 8 PROPOSAL NO. 1 ELECTION OF DIRECTORS COMMITTEES AND MEETINGS OF THE BOARD OF DIRECTORS Director Meetings. The business of the Company is under the general management of its Board of Directors as provided by the Company's by-laws and the laws of Tennessee, the Company's state of incorporation. The Board of Directors regularly meets quarterly during the Company's fiscal year. There are presently eight directors, six of whom are not executive officers or employees of the Company ("Independent Directors"). The Board of Directors held three meetings during fiscal 1998. No director attended fewer than 75% of the meetings of the Board of Directors and committees during the year. Executive Committee. The Board of Directors has established an Executive Committee, which currently consists of Messrs. Bumstead, Jacobs and Seward, each of whom is an Independent Director, Mr. Clark and Dr. West. The Executive Committee was created to have more routine, detailed meetings with management and is empowered to act on behalf of the Board of Directors between meetings when such action is considered necessary. The Executive Committee met three times during fiscal 1998. Audit Committee. The Board of Directors has established an Audit Committee, which currently consists of Messrs. Bumstead, Kugelman, Jacobs and Seward (Chairman) each of whom is an Independent Director. The Audit Committee provides assistance and advice to the board of directors on auditing and related matters and reviews management's selection of independent auditors. The Audit Committee met four times during fiscal 1998. Nominating and Compensation Committee. The Board of Directors has established a Compensation Committee, which currently consists of Messrs. Bumstead, Kugelman, Jacobs (Chairman) and Seward each of whom is an Independent Director. The Compensation Committee reviews compensation, including stock incentives, of the Company's executive officers, and makes recommendations to the Board of Directors with respect to such compensation matters. The Compensation Committee also administers the Company's 1990 Non-Qualified Stock Option Plan and the 1996 Stock Incentive Plan. The Compensation Committee serves as the Nominating Committee of the Company. The Compensation Committee met three times during fiscal 1998. COMPENSATION OF DIRECTORS Directors who are executive officers or employees of the Company do not receive additional remuneration as directors. Independent Directors receive an annual retainer fee of $10,000, $1,500 for each board meeting attended, and $750 for each committee meeting attended. Such compensation is payable in respect of all duly noticed meetings and is payable whether the director attends in person or by telephone. Such compensation may be deferred at the election of the director and paid later in cash or in shares of Common Stock. Independent Directors are granted options to purchase 1,000 shares of Common Stock during each calendar quarter of service as a director of the Company. To ensure compliance with Rule 16b-3 under the Securities Exchange Act of 1934, no options granted to such Independent Directors may be exercised earlier than six months from the date of the grant. All directors of the Company are eligible to receive reimbursement of expenses, if any, incurred in attending meetings of the board of directors and committees thereof. NOMINEES FOR DIRECTORS The Company's Charter divides the board of directors into three classes, with each having not less than one director nor more than five directors. Class I directors are elected for terms of three years; Class II directors for terms of two years; and Class III directors for terms of one year. The Board of Directors has set at eight the number of directors constituting the full Board of Directors. 7 9 The following three individuals have been nominated for election to serve as directors of the Company. Messrs. Clark, Seward and Grant are currently directors of the Company. See "Certain Transactions with Directors" and "Business Relationships between Company and Directors." The remaining members of the Board of Directors listed below will continue as members thereof until their respective terms expire as indicated below. Unless a shareholder specifies otherwise, it is intended that such shareholder's shares of Common Stock will be voted FOR the election of the nominees to serve as directors until the expiration of their respective terms and until their successors are elected and qualified. If any nominee shall become unavailable or unwilling to serve the Company as a director for any reason, the persons named in the Proxy Form are expected to consult with the management of the Company in voting the shares represented by them. The Board of Directors has no reason to doubt the availability of any of the nominees, and each has indicated his willingness to serve as a director of the Company if elected. DIRECTOR NOMINEES - CLASS III (TERMS EXPIRING 2000) JOSEPH T. CLARK, age 43, has been a director of the Company since 1988. Mr. Clark has served as the Chief Executive Officer of the Company since January 1996 and as President of the Company since February 1993. Mr. Clark was formerly the Executive Vice President and Chief Operating Officer of the Company from May 1989 to February 1993 and Secretary of the Company from September 1988 to February 1993. Mr. Clark also served as Chief Financial Officer of the Company from March 1988 to May 1989. Committees: Executive JAMES R. SEWARD, age 46, has been a director of the Company since 1990. Mr. Seward served as the President and Chief Executive Officer of SLH Corporation from December 1996 to August 1998 and is presently the manager of Seward and Company, L.L.C., a consulting entity. Mr. Seward previously served as the Executive Vice President of Seafield Capital Corporation from May 1993 to July 1997 and was the Senior Vice President of Seafield Capital Corporation from August 1990 to May 1993. Mr. Seward also served as the Chief Financial Officer of Seafield Capital Corporation from February 1991 to July 1997. Mr. Seward serves as a Director of Lab One, Inc., Concorde Career Colleges and Syntroleum, Inc. Mr. Seward is a Chartered Financial Analyst. Committees: Compensation, Executive, and Audit (Chairman) W. THOMAS GRANT II, age 48, has been a director of the Company since 1991. Mr. Grant has been the Chief Executive Officer of Lab One, Inc. since July 1997. Mr. Grant was the Chief Executive Officer of Seafield Capital Corporation and served as the Chairman of the Board of Seafield Capital Corporation from May 1993 to July 1997, prior to which time he served as the President. Mr. Grant serves as a director for AMC Entertainment, Inc., Kansas City Power & Light Company, Commerce Bancshares, Inc., Lab One, Inc. and SLH Corporation. Committees: None INCUMBENT DIRECTORS - CLASS I (TERMS EXPIRING 2001) WILLIAM H. WEST, M.D., age 51, has been a director of the Company since 1985. He has served as Chairman of the Board of Directors of the Company since February 1993. Dr. West served as Chief Executive Officer of the Company from May 1989 to January 1996 and Medical Director of the Company from 1985 to February 1996. Dr. West served as President of the Company from May 1989 to February 1993. Committees: Executive 8 10 FRANK M. BUMSTEAD, age 57, has been a director of the Company since 1985. He has served as the Vice-Chairman of the Board of the Company since February 1993. Mr. Bumstead was the Chairman of the Board of the Company from January 1989 to February 1993. He has been the President and Chief Executive Officer of Flood, Bumstead, McCready and McCarthy, Inc., a financial management and business consulting firm, since January 1990. Mr. Bumstead is also a director of First Union National Bank of Tennessee, Syntroleum Inc., American Retirement Corporation, TBA Entertainment, Inc and Imprint Records, Inc., serving on the compensation committees of the latter two companies. Mr. Bumstead serves as the Chairman of the executive committee of American Retirement Corporation Committees: Compensation, Executive (Chairman), and Audit LEONARD A. KALMAN, M.D., age 48, has been a director of the Company since 1996. Dr. Kalman is a practicing medical oncologist with Oncology Hematology Group of South Florida, P.A., where he has practiced for more than 7 years. Committees: None INCUMBENT DIRECTORS - CLASS II (TERMS EXPIRING 2001) P. ANTHONY JACOBS, age 57, has been a director of the Company since 1990. Since September, 1997 Mr. Jacobs has served as President of CEO of Lab Holdings, Inc. From May 1993 to September 1997 Mr. Jacobs served as President of Seafield Capital Corporation and as Chief Operating Officer from May 1990 to September 1997. From December 1996 to August 1998, Mr. Jacobs also served as Chairman of the Board of SLH Corporation. Mr. Jacobs is a director of Lab Holdings, Inc., Trenwick Group, Inc., and Syntroleum, Inc. Committees: Compensation (Chairman), Executive, and Audit LAWRENCE N. KUGELMAN, age 56, has been a director of the Company since August 1996. Mr. Kugelman has been a self-employed health care consultant since October 1996. From December 1995 to October 1996, he served as President and Chief Executive Officer of Coventry Corp. From April 1995 to December 1995, Mr. Kugelman was a self-employed health care consultant. From January 1993 to April 1995, he was Executive Vice President of American Medical International, and prior to that he was President and Chief Executive Officer of Health Plan of America. Mr. Kugelman is also a director of Coventry Corp. Committees: Compensation and Audit 9 11 CERTAIN TRANSACTIONS WITH DIRECTORS In January 1996, the Company acquired from Dr. Kalman all common stock owned by Dr. Kalman in Oncology Hematology Group of South Florida, P.A. (the "Group") for an aggregate purchase price of approximately $1,540,000. As partial consideration for the acquisition, the Company executed a promissory note payable to the stockholders of the Group in the principal amount of approximately $5,960,000, of which Dr. Kalman's beneficial interest is approximately $745,000. The note bears interest at the rate of 9% per annum and is payable in 59 consecutive equal amortized installments of principal and interest. Payments on the note may be received, at the election of the Group, in shares of Common Stock based on a conversion rate of $11.50 per share. As of the date hereof, approximately $965,000 remains payable to the Group of which Dr. Kalman's beneficial interest is approximately $120,000. BUSINESS RELATIONSHIPS BETWEEN COMPANY AND DIRECTORS The Company and the Group, of which Dr. Kalman is a stockholder, are parties to a management services agreement, executed in January 1996 and amended in August 1997 in connection with the above-described physician practice affiliation transaction, pursuant to which the Group pays the Company service fees in exchange for the Company managing all of the non-medical aspects of the Group's oncology practice. The agreement presently provides for the payment by the Group of service fees equal to a percentage of the practice's net operating income plus clinic expenses. During 1998, the Group paid the Company aggregate service fees of approximately $8,500,000. EXECUTIVE COMPENSATION EXECUTIVE OFFICERS OF THE COMPANY WILLIAM H. WEST, M.D., CHAIRMAN: Dr. West has served as Chairman of the Board since February 1993 and Chief Medical Officer since October 1998. Previously, he served as Chief Executive Officer from May 1989 to January 1996 and as Chief Medical Officer from 1985 to February 1996. Dr. West, who is a medical oncologist and founder of the West Clinic (a medical oncology clinic in Memphis), has been a Director of the Company since 1985. In addition, Dr. West has served as a Senior Researcher at the National Cancer Institute and he has had numerous articles published in major industry publications, including THE NEW ENGLAND JOURNAL OF MEDICINE. JOSEPH T. CLARK, PRESIDENT AND CHIEF EXECUTIVE OFFICER: Mr. Clark has served as Chief Executive Officer of the Company since January 1996 and President since February 1993. From 1978 to 1982, Mr. Clark served as a hospital administrator with Humana. From 1982 to 1988, he was with American Medical International in various capacities, including Regional Director of Finance. Mr. Clark has been a Director of the Company since 1988. MARY E. CLEMENTS, CHIEF FINANCIAL OFFICER: Ms. Clements has been Chief Financial Officer of the Company since June 1997. Before joining Response Oncology in June 1996, she served in a number of capacities at Coopers & Lybrand L.L.P., performing various auditing and consulting functions for several physician practice management companies. From June 1996 to September 1996, Ms. Clements served as Director of Development for the Company's Practice Management Division. In September 1996, she was appointed Chief Operating Officer of that Division. KENNETH L. SCOTT, CHIEF OPERATING OFFICER: Mr. Scott has been Chief Operating Officer of the Company since January 1997. From February 1996 to January 1997, he served as Chief Operating Officer of the Company's IMPACT division. Previously, Mr. Scott was President and Chief Executive Officer of American Health Care Management Services, Inc., an oncology healthcare management consulting company, from June 1993 to February 1996. CARLTON N. SEDBERRY, EXECUTIVE VICE PRESIDENT OF DEVELOPMENT: Mr. Sedberry has been Executive Vice President of Development for the Company since May 1997. Previously, he served as Vice President of Development of the Company's IMPACT Division from January 1996 to May 1997, as the Western Region Director of Operations from June 1993 to January 1996 and as Director of Pharmacy from September 1989 to June 1993. Prior to joining the Company Mr. Sedberry served as Director of Southeast Region for Pharmacy Operations of National Medical Enterprises, Inc. 10 12 EMPLOYMENT CONTRACTS; CHANGE OF CONTROL ARRANGEMENTS Each of the executive officers named in the tables below has executed, effective as of January 1, 1998, an employment contract providing for the continued employment of each of the named executives. Each contract is for a term of three years and is automatically renewed for a one year period unless notice of termination is given on the anniversary date preceding its expiration. The employment contracts provide for the following base salaries, plus in each case a bonus of up to 100% of the executive's base salary: Dr. West - $234,000; Mr. Clark - $234,000; Mr. Scott - $185,000; Ms. Clements - $150,000 and Mr. Sedberry - $115,000. Annual bonuses are determined in accordance with policies, and are based on performance targets, established by the Compensation Committee. In addition, each executive is entitled to all other employee benefits for which any salaried employee of the Company is eligible. Each employment contract provides for termination of salary as of the date of termination due to death or disability, as well as upon a termination for cause by the Company or voluntary termination by the executive. Cause is defined as conviction of a felony, perpetration of fraud, embezzlement or other act of dishonesty or the executive's breach of trust or fiduciary duties in a manner that materially adversely affects the Company or its shareholders. If an executive's employment is terminated by the Company without cause or the executive suffers a "constructive termination" of employment (defined as (a) a declined reassignment to a job that is not the equivalent of the executive's then-current position either in terms of scope of duties or location of employment, or (b) conduct by the Company or the board of directors that is a continuous and material interference with the executive's ability to perform the duties of his position), and there has not been a change in control of the Company, then the executive is entitled a lump sum severance payment equal to 100% of his or her then-current base salary plus 100% of the average annual incentive bonus paid to the executive during the two years immediately preceding such termination. In the event the executive's employment is terminated without cause or the executive suffers a constructive termination within one year following a change in control, the executive is entitled to a lump sum severance payment equal to (1) 200% (299% in the case of Dr. West and Mr. Clark) of the sum of the executive's base salary as in effect at the time of termination plus the executive's average annual incentive bonus for the two years immediately preceding such termination, plus (2) the amount of any excise tax incurred by the executive pursuant to the "excess parachute payment" rules under the Internal Revenue Code of 1996, as amended; provided that the foregoing excise tax gross-up is limited for all executives of the Company to an aggregate amount of $5 million. While the executive is employed by the Company and for a period of one year following termination of employment for any reason (except upon the Company's failure to renew), the executive has agreed not to compete with the Company. 11 13 COMPENSATION TABLES The following table sets forth the compensation for services rendered for each of the Company's last three fiscal years, of the Chief Executive Officer and the Company's other four most highly compensated executive officers whose total annual salary and bonus exceeded $100,000: SUMMARY COMPENSATION TABLE
ANNUAL LONG TERM COMPENSATION COMPENSATION AWARDS - -------------------------------------------------------------------------------------------------------- NAME AND PRINCIPAL OPTIONS/ LTIP ALL OTHER POSITION YEAR SALARY BONUS SARs PAYOUTS COMPENSATION - -------------------------------------------------------------------------------------------------------- 1998 $234,000 $ 70,200 0 0 $1,250 (1) Joseph T. Clark, 1997 212,954 110,837 344,749 0 1,250 (1) President and CEO 1996 205,231 50,800 25,000 0 1,358 (1) Mary E. Clements 1998 $150,000 $ 45,000 0 0 $1,250 (1) Chief Financial Officer 1997 127,539 62,421 130,000 0 1,154 (1) 1996 38,462 15,000 75,000 0 0 1998 $185,000 $ 55,500 0 0 $1,250 (1) Kenneth L. Scott 1997 175,000 90,030 157,331 0 1,250 (1) Chief Operating Officer 1996 120,192 25,850 120,000 0 1,053 (1) Carlton N. Sedberry 1998 $115,000 $ 69,000 0 0 $1,250 (1) Executive Vice President 1997 104,375 69,000 120,555 0 1,250 (1) of Development 1996 94,584 49,700 4,000 0 1,250 (1) 1998 $234,000 $ 70,200 0 0 $ 0 1997 234,000 110,837 209,149 0 0 William H. West, M.D. 1996 230,885 49,300 25,000 0 108 (1) Chairman
(1) Reflects Company contributions paid or accrued to the named executive's account in the Company's 401(k) Profit Sharing Plan and Trust and premiums paid for term life insurance. 12 14 Option Grants as of December 31, 1998. No option grants were made to any of the Company's executive officers during the 1998 fiscal year. Aggregated Option Exercises through December 31, 1998. The following table provides information with respect to the value of each of their unexercised options at December 31, 1998. No executive officer exercised any options during the year ended December 31, 1998. AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUES
Number of Shares Underlying Value of Unexercised Unexercised Options In-the-Money Options at Fiscal Year End at December 31, 1998(1) --------------------------------------------------------------------- Name Exercisable Unexercisable Exercisable Unexercisable ---- ----------- ------------- ----------- ------------- Joseph T. Clark 383,549 0 $ 91,194 $0 Mary E. Clements 130,000 0 $ 0 $0 Kenneth L. Scott 157,331 0 $ 0 $0 Carlton N. Sedberry 126,555 0 $ 11,878 $0 William H. West 259,149 0 $ 50,060 $0
(1) Based upon the closing price of $4.06 per share of the Common Stock on the The Nasdaq Stock Market on December 31, 1998. 13 15 REPORT OF THE COMPENSATION COMMITTEE The Compensation Committee of the Board of Directors (the "Committee") is composed entirely of Independent Directors. The Committee meets periodically to review and recommend for Board approval the Company's compensation program for senior executives and other key employees and independently administers the stock option and other incentive plans of the Company. The guiding principle of the Committee is to establish a compensation program which aligns executive compensation with the Company's objectives, business strategies and financial and operational performance. In connection with this principle, the Committee seeks to: (1) Attract and retain qualified executives in the highly competitive health care industry who will play a significant role in the achievement of the Company's goals. (2) Create a performance oriented environment that rewards performance with respect to the financial and operational goals of the Company and which takes into account industry-wide trends and performance levels. (3) Reward executives for the strategic management and the long-term enhancement of shareholder value. Compensation for the key executives consists of three elements: base salary and benefits, a performance based annual cash bonus and stock-based compensation. While the Committee seeks to weigh each element separately, it is their collective value that is considered in ensuring that the executive officers are appropriately compensated in a manner that advances both the short-term and long-term interests of the shareholders. The base salary for each executive officer is set on the basis of the salary levels in effect for comparable positions in the industry, adjusted for the executive's experience and performance level and internal comparability considerations. The Company monitors industry salary levels with the assistance of a compensation consultant. For 1998, the committee believes the executive officers' base salaries were competitive with salaries for individuals in comparable positions based on an industry survey commissioned by the Committee. INCENTIVE COMPENSATION An executive officer's performance-based annual cash bonus is based upon pre-established financial goals as well as the achievement of strategic objectives and milestones. The primary financial goal set by the Committee has been achievement of target levels of earnings before interest and taxes (EBIT). An aggregate incentive pool is determined by taking a percentage of EBIT and allocating it among participants. In establishing a minimum level of EBIT before any bonuses are earned the Committee considers prior fiscal year performance and the amount of increase budgeted for the coming year. The percentage of EBIT credited to the bonus pool may be increased if actual EBIT exceeds budgeted EBIT. Based upon the CEO's recommendation as to the participant's contribution to the overall success in achieving the EBIT results, officers may earn from 10% to 100% of base salary. Achievement of strategic objectives and milestones may also be a portion of an individual's performance-based annual cash bonus, including the number of new IMPACT Center openings, development of infrastructure necessary to sustain future growth, obtaining financing on favorable terms, or more recently with diversification into the physician practice management business and the number of physicians under management. For 1998, the Committee placed significant emphasis on the fact that large reserves with respect to three unprofitable physician practice management relationships were recorded in the fourth quarter resulting in an annual loss, reducing incentive compensation significantly below 1997 levels. 14 16 STOCK INCENTIVES Pursuant to the Company's various stock option and incentive plans, the Committee periodically awards stock options to executive officers, key employees, and consultants to the Company and its subsidiaries. Pursuant to the 1996 Stock Incentive Plan the Committee has the ability to award shares of restricted stock and stock appreciation rights (whether separate or in tandem with stock options) in addition to stock options. Such stock based compensation provides for an incentive for each participant to become a meaningful shareholder of the Company and provides a mechanism for aligning those participants' interests with those of the shareholders. The Committee believes that such stock option grants are the foundation in the overall compensation packages of the Company's senior management because such grants recognize both productivity and profitability, while at the same time giving recipients a vested long term interest in the success of the Company through stock ownership. COMPENSATION OF CHIEF EXECUTIVE OFFICER Mr. Clark's base salary is set using the same criteria as all other executive officers. His 1998 cash bonus was substantially less than his 1997 cash bonus primarily because of the Company's large fourth quarter and annual losses resulting from substantial additional reserves being established with respect to three unprofitable physician practice management relationships. Mr. Clark's cash bonus was 50% of the maximum bonus provided in his employment agreement. COMPENSATION COMMITTEE P. Anthony Jacobs (Chairman) Frank M. Bumstead Lawrence Kugelman James R. Seward 15 17 PERFORMANCE GRAPH The graph below sets forth the cumulative total return to Response Oncology, Inc.'s shareholders during the five year period ended December 31, 1998, as well as an overall stock market index (Nasdaq U.S. Index) and a peer group index (Nasdaq Health Services Index). The Company has changed its peer group index from the S&P Health Care Services Index to the Nasdaq Health Services Index. The Company has made this change because it believes the companies comprising the Nasdaq Health Services Index are more comparable in terms of size and market capitalization than those comprising the S&P Health Care Services Index. The stock performance graph assumes $100 was invested on December 31, 1993:
12/31/93 12/31/94 12/31/95 12/31/96 12/31/97 12/31/98 -------- -------- -------- -------- -------- -------- Response Oncology $ 100.00 $ 103.85 $ 153.85 $ 116.92 $ 103.14 $ 49.97 Nasdaq U.S. Index $ 100.00 $ 97.75 $ 138.26 $ 170.02 $ 208.58 $ 293.21 Nasdaq Health Services Index $ 100.00 $ 107.29 $ 136.11 $ 135.89 $ 138.49 $ 118.76 S&P Health Care Services Index $ 100.00 $ 64.29 $ 88.394 $ 92.407 $ 116.12 $ 209.21
16 18 COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION IN COMPENSATION DECISIONS There were no compensation interlocks in 1998, and no insider participated in decisions relating to his compensation in 1998. COMPLIANCE WITH SECTION 16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Section 16(a) of the Securities Exchange Act of 1934 requires the Company's directors, executive officers and persons who own more than 10% of the registered class of the Company's equity securities to file reports of ownership with the Securities and Exchange Commission. Such directors, executive officers and shareholders are required pursuant to Securities and Exchange Commission regulations to furnish the Company with copies of all reports filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. Based solely on a review of the Forms 3 and 4, and amendments thereto, furnished to the Company during the fiscal year ended December 31, 1998 and Form 5, and amendments thereto, furnished to the Company with respect to such fiscal year, and certain representations furnished to the Company, the Company believes that during the fiscal year ended December 31, 1998 all reports under Section 16(a) of the Securities Exchange Act of 1934 required to be filed by directors, executive officers and 10% shareholders of the Company were timely filed. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH OF THE NOMINEES FOR CLASS III DIRECTORS. 17 19 PROPOSAL 2. RATIFICATION OF SELECTION OF KPMG LLP AS THE 1999 INDEPENDENT ACCOUNTANTS AND AUDITORS The Board of Directors has selected KPMG LLP as the Company's independent auditors for 1999. The selection is subject to approval by the shareholders not later than the date of the Annual Meeting. KPMG LLP served as independent auditors of the Company for the years ended December 31, 1993 through 1998. Representatives of the firm will be present at the Annual Meeting, have an opportunity to make a statement if they so desire and are expected to be available to respond to appropriate questions. The affirmative vote of the holders of a majority of the outstanding shares of Common Stock entitled to vote at the Meeting is required to ratify the selection of KPMG LLP as the Company's independent auditors for 1999. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ADOPTION OF PROPOSAL NO. 2. 18 20 SHAREHOLDER PROPOSALS FOR 2000 Pursuant to the Securities Exchange Act of 1934, shareholder proposals intended to be presented at the 2000 annual meeting of shareholders of the Company must be received by the Company at its executive offices on or before January 10, 2000. OTHER MATTERS The Board of Directors knows of no other business to be brought before the meeting. If any other matters properly come before the meeting, the proxies will be voted on such matters in accordance with the judgment of the persons named as proxies therein, or their substitutes, present and acting at the meeting. INCORPORATION BY REFERENCE The consolidated financial statements of the Company, included in the Company's 1998 Annual Report which accompanies this Proxy Statement, are hereby incorporated by reference into this Proxy Statement as if stated verbatim herein. BY ORDER OF THE BOARD OF DIRECTORS MARY E. CLEMENTS Secretary April 25, 1999 19 21 RESPONSE ONCOLOGY, INC. PROXY FOR ANNUAL MEETING OF SHAREHOLDERS JUNE 10, 1999 The Undersigned hereby appoints Mary E. Clements as true and lawful attorney or attorney-in-fact of the undersigned, with full power of substitution, to vote a proxy for the undersigned at the Annual Meeting of the Shareholders for Response Oncology, Inc. (the "Company") to be held at the Company's corporate offices located at 1805 Moriah Woods Boulevard, Memphis, Tennessee at 11:00 a.m., local time, on June 10, 1999, and all adjournments thereof, the number of shares of which the undersigned would be entitled to vote if then personally present for the following purposes: 1. To elect three Class III directors to serve one year terms ending in 2000, or until their successors have been duly elected and qualified. [ ] FOR all nominees listed below [ ] AGAINST all nominees listed below [ ] ABSTAIN (except as marked to the contrary below) - -------------------------------------------------------------------------------- INSTRUCTION: To withhold authority to vote for any individual nominee, strike a line through the nominee's name in the list below: Class III Directors: Joseph T. Clark W. Thomas Grant, II James R. Seward 2. To ratify the selection of KPMG LLP as the Company's independent auditors for 1999. [ ]FOR [ ] AGAINST [ ] ABSTAIN (Continued on reverse side) (Continued from other side) This proxy, which is solicited on behalf of the Board of Directors of Response Oncology, Inc. will be voted in the manner described herein. If no direction is made, this proxy will be voted FOR all the proposals listed. Date: , 1999 ----------------------------- ------------------------------- Signature ------------------------------- Signature if Held Jointly NOTE: Please date and sign exactly as name appears hereon. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If a corporation, please sign full name by authorized officer. -----END PRIVACY-ENHANCED MESSAGE-----